Evidence map›Paper›PMID 42507335›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

SEOM‑GETTHI clinical guideline for the practical management of molecular platforms (update 2026).

Nuria Rodriguez Salas, Juan de la Haba-Rodriguez, Ferran Ferragut Lloret, Maria Angeles Vaz Salgado, Martín Oré Arce, Ana Cardeña Gutiérrez, Carmen Beato Zambrano, Rosa María Rodríguez Alonso, Rafael López López, Jesús García-Donas Jiménez

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nuria Rodriguez SalasDepartment of Medical Oncology, Hospital La Paz, Madrid, Spain. nuria.rodriguez@salud.madrid.org.ORCID http://orcid.org/0000-0001-7863-6103
Juan de la Haba-RodriguezDepartment of Medical Oncology, Hospital Universitario Reina Sofia, Instituto Maimonides de Investigacion Biomedica, Universidad de Córdoba, Córdoba, Spain.
Ferran Ferragut LloretDepartment of Medical Oncology, Hospital General Universitario, Ciudad Real, Spain.
Maria Angeles Vaz SalgadoDepartment of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Martín Oré ArceDepartment of Medical Oncology, Hospital Marina Baixa de Villajoyosa, Alicante, Spain.
Ana Cardeña GutiérrezDepartment of Medical Oncology, Hospital Universitario Nuestra Señora de La Candelaria, Tenerife, Spain.
Carmen Beato ZambranoDepartment of Medical Oncology, Hospital Universitario de Jerez de La Frontera, Cádiz, Spain.
Rosa María Rodríguez AlonsoDepartment of Medical Oncology, Hospital Universitario Reina Sofía, Córdoba, Spain.
Rafael López LópezDepartment of Medical Oncology, Complejo Hospitalario Universitario de Santiago, A Coruña, Spain.
Jesús García-Donas JiménezDepartment of Medical Oncology, Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identification of molecular alterations in cancer and advances in technology have enhanced the use of molecular alterations for the diagnosis and treatment of cancer in routine clinical practice. Multi-determination platforms are now available in most Spanish hospitals. First developed in 2021, the objective of these clinical practice guidelines is to review the usefulness of molecular platforms and establish usage guidelines to direct their incorporation into clinical practice. Here, we provide updated guidelines, which include the most recent advancements in this area.

Indexed as

BiomarkersMolecular platformsNext-generation sequencingPrecision medicine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.